O-GlcNAcylation, oxidation and CaMKII contribute to atrial fibrillation in type 1 and type 2 diabetes by distinct mechanisms
Olurotimi O. MesubiiD, Adam G. Rokita, Neha Abrol, Yuejin WuiD, Biyi CheniD, Qinchuan WangiD, Jonathan M. GrangeriD, Anthony Tucker-BartleyiD, Elizabeth D. LuczakiD, Kevin R. MurphyiD, Priya UmapathiiD, Partha S. Banerjee, Tatiana N. BoroninaiD, Robert Norman ColeiD, Lars Siegfried MaieriD, Xander H.T. WehrensiD, Joel L. PomerantziD, Long‐Sheng SongiD, Rexford S. AhimaiD, Gerald Warren HartiD, Natasha Elizabeth ZacharaiD, Mark E. AndersoniD
Abstract
Diabetes mellitus and atrial fibrillation (AF) are major unsolved public health problems, and diabetes is an independent risk factor for AF in patients. However, the mechanism(s) underlying this clinical association is unknown. Elevated protein O-GlcNAcylation (OGN) and reactive oxygen species (ROS) are increased in diabetic hearts, and calmodulin kinase II (CaMKII) is a proarrhythmic signal that may be activated by OGN (OGN-CaMKII) and ROS (ox-CaMKII). We induced type 1 (T1D) and type 2 diabetes (T2D) in a portfolio of genetic mouse models capable of dissecting the role of OGN and ROS at CaMKII and the type 2 ryanodine receptor (RyR2), an intracellular Ca2+ channel implicated as an important downstream mechanism of CaMKII- mediated arrhythmias. Here we show that T1D and T2D significantly increased AF, similar to observations in patients, and this increase required CaMKII. While T1D and T2D both require ox-CaMKII to increase AF, they respond differently to loss of OGN-CaMKII or OGN inhibition. Collectively, our data affirm CaMKII as a critical proarrhythmic signal in diabetic AF, and suggest ROS primarily promotes AF by ox-CaMKII, while OGN promotes AF by diverse mechanisms and targets, including CaMKII and RyR2. The proarrhythmic consequences of OGN- and ox-CaMKII differ between T1D and T2D. These results provide new and unanticipated insights into the mechanisms for increased AF in diabetes mellitus, and suggest successful future therapies will need to be different for AF in T1D and T2D.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Differential effects of obesity and diabetes on the action potential waveform and inward currents in rat ventricular myocytes.
Anatoliy Shmygol, Gilles Bru‐Mercier, … Frank Christopher Howarth·Clinical SciencePeer-reviewed·Dec 18, 2024
- SGLT2 inhibitors protect against diabetic cardiomyopathy and atrial fibrillation through a CaMKII independent mechanism
Alex Severino, Oscar E. Reyes Gaido, … Olurotimi O. Mesubi·bioRxiv·Sep 23, 2024
- Nrf2 prevents diabetic cardiomyopathy via antioxidation and normalization of glucose and lipid metabolism in the heart
Ge Yang, Qihe Zhang, … Ying Xin·bioRxiv·Apr 4, 2022
- Integrative human atrial modeling unravels interactive PKA and CaMKII signaling as key determinant of atrial arrhythmogenesis
H. Ni, S. Morotti, … E. Grandi·bioRxiv·Apr 27, 2022
- Myocardial cGMP-PKG1alpha dysregulation contributes to VT pathogenesis in type II diabetes and metabolic syndrome.
Xuehong Cao, Yali Zhang, … Jonas Galper·bioRxiv·Feb 12, 2025
- Fibronectin improves the impaired calcium signaling and myofilament activation in diabetic cardiomyocytes
X. Wu, J. P. Trzeciakowski, … M. Muthuchamy·bioRxiv·Nov 15, 2022